{
    "nctId": "NCT04435028",
    "briefTitle": "Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy",
    "officialTitle": "Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Iron Chelation",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent),\n* aged 30-60, and\n* female subjects were included as they were female breast cancer patients, and,\n* patients who had an adequate baseline echocardiography.\n\nExclusion Criteria:\n\n* who had a history of heart failure,\n* arrhythmia,\n* cardiac catheterizations,\n* angina,\n* uncontrolled hypertension, and\n* uncontrolled diabetes,\n* patients with impaired liver function tests,\n* patients who previously received anthracycline-containing regimens, and\n* any cardiotoxic chemotherapy regimens, previous history of chest wall irradiation.\n* Brian metastasis.",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT"
}